Zivo Bioscience effects 1-for-6 reverse stock split to regain Nasdaq compliance

Zivo Bioscience, Inc.

1-for-6 reverse split effective 5:00 p.m. ET Oct 26, 2023; trading split-adjusted Oct 27.
Authorized shares reduced from 150M to 25M; par value $0.001 unchanged.
No fractional shares issued; cash in lieu based on Oct 26 closing price.
Proportional adjustments to warrants, stock options, and equity plan shares.
Reverse split intended to meet Nasdaq continued listing requirements.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Zivo Bioscience, Inc.: Amended articles to effect a 1-for-6 reverse stock split and reduce authorized common shares from 150,000,000 to 25,000,000 (effective 2023-10-26).

Change: charter amendment
Effective: 2023-10-26

Exact text from the filing

On October 24, 2023, Zivo Bioscience, Inc. (the “Company”) filed a certificate of amendment to its articles of incorporation with the Secretary of State of the State of Nevada (the “Certificate of Amendment”) to (i) effectuate a reverse stock split (the “Reverse Stock Split”) of its issued and outstanding shares of common stock and treasury shares on a 1-for-6 basis and (ii) decrease the number of total authorized shares of Common Stock of the Company from 150,000,000 to 25,000,000 shares.

View on SEC.gov

Browse all governance changes →

Zivo Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-23-013408

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.